Fritz Offner

17.4k total citations · 3 hit papers
236 papers, 6.1k citations indexed

About

Fritz Offner is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Fritz Offner has authored 236 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Pathology and Forensic Medicine, 98 papers in Genetics and 84 papers in Oncology. Recurrent topics in Fritz Offner's work include Lymphoma Diagnosis and Treatment (118 papers), Chronic Lymphocytic Leukemia Research (94 papers) and CAR-T cell therapy research (42 papers). Fritz Offner is often cited by papers focused on Lymphoma Diagnosis and Treatment (118 papers), Chronic Lymphocytic Leukemia Research (94 papers) and CAR-T cell therapy research (42 papers). Fritz Offner collaborates with scholars based in Belgium, United States and United Kingdom. Fritz Offner's co-authors include Jan Philippé, Ann Janssens, Lucien Noens, Sofie Lust, Bertrand Coiffier, Michael Crump, Dominique Benoît, Raoul Herbrecht, Gregor Verhoef and Johan Decruyenaere and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Fritz Offner

226 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009 485 citations Georg Heß, Gregor Verhoef et al. Journal of Clinical Oncology profile →
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

2019 312 citations Jan A. Burger, Paul M. Barr et al. profile →
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

2022 146 citations Paul M. Barr, Carolyn Owen et al. profile →

Peers

Countries citing papers authored by Fritz Offner

Since Specialization

Citations

This map shows the geographic impact of Fritz Offner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fritz Offner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fritz Offner more than expected).

Fields of papers citing papers by Fritz Offner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fritz Offner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fritz Offner. The network helps show where Fritz Offner may publish in the future.

Co-authorship network of co-authors of Fritz Offner

This figure shows the co-authorship network connecting the top 25 collaborators of Fritz Offner. A scholar is included among the top collaborators of Fritz Offner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fritz Offner. Fritz Offner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER’S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL 2024 ·University of Southern Denmark Research Portal (University of Southern Denmark) ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, (unknown), Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, (unknown), А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, (unknown)	1
2	Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 2024 ·Journal of Clinical Oncology ·Yasmin Karimi, Pau Abrisqueta, Sven de Vos, Marcel Nijland, Fritz Offner, (unknown), (unknown), (unknown), (unknown), Raúl Córdoba, Lorenzo Falchi	7
3	IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Lorenzo Falchi, Joost S.P. Vermaat, Gerardo Musuraca, Marcel Nijland, Jacob Haaber Christensen, Fritz Offner, Lori A. Leslie, Joshua Brody, Daniela Hoehn, (unknown), Liwei Wang, Jian Mei, David Belada, Pau Abrisqueta	1
4	CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, Edith Szafer‐Glusman, Cathy Zhou, Anita Szőke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	4
5	Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose Sandoval‐Sus, Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, (unknown), А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, (unknown)	2
6	Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study. 2024 ·Journal of Clinical Oncology ·Tycel Phillips, Carmelo Carlo‐Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Maciej Zaucha, Tomasz Wróbel, Fritz Offner, (unknown), James Relf, David Carlile, Ben Byrne, (unknown), Linda Lundberg, Michael Dickinson	7
7	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) 2021 ·Blood ·Franck Morschhauser, Carmelo Carlo‐Stella, Michael Dickinson, Tycel Phillips, Roch Houot, Fritz Offner, Corinne Haïoun, Paolo Corradini, Martin Hutchings, Anna Sureda, Joaquín Martínez‐López, Tomasz Wróbel, Shang‐Ju Wu, Linda Lundberg, (unknown), David Pérez-Callejo, James Relf, Anesh Panchal, Kathryn Humphrey, Emmanuel Bachy	20
8	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies 2017 ·Clinical Cancer Research ·Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean‐Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean‐Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, Ahmad Awada	47
9	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma 2015 ·Clinical Cancer Research ·Markus Hansson, Peter Gimsing, Ashraf Badros, (unknown), Hareth Nahi, Fritz Offner, Morten Salomo, (unknown), Morten Mau‐Sørensen, (unknown), (unknown), Ingrid Teige, Jan Van Droogenbroeck, (unknown), Maurizio Zangari, Björn Frendéus, Magnus Korsgren, Martine Poelman, Guido Tricot	42
10	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL 2015 ·Blood ·Fritz Offner, Olga Samoilova, Evgenii A. Osmanov, Hyeon‐Seok Eom, Max S. Topp, João Raposo, (unknown), Deborah Ricci, Shalini Chaturvedi, Eugene Zhu, Helgi van de Velde, Christopher Enny, Aleksandra Rizo, Burhan Ferhanoğlu	98
11	Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone 2014 ·British Journal of Haematology ·Gareth J. Morgan, Antonio Palumbo, Sujith Dhanasiri, Dawn Lee, Katja Weisel, Thierry Façon, Michel Delforge, Albert Oriol, Mohamed H. Zaki, Xin Yu, Lars Sternås, Christian Jacques, Ron Akehurst, Fritz Offner, Meletios Α. Dimopoulos	14
12	Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone 2014 ·Ghent University Academic Bibliography (Ghent University) ·Gillian Morgan, Jesús F. San Miguel, Sujith Dhanasiri, (unknown), Antonio Palumbo, Thierry Façon, Mohamed H. Zaki, Xiaoyan Yu, Lars Sternås, Christian Jacques, Katja Weisel, Fritz Offner, Meletios Α. Dimopoulos	1
13	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab 2013 ·Journal of Clinical Oncology ·Luis Fayad, Fritz Offner, Mitchell R. Smith, Gregor Verhoef, Peter Johnson, Jonathan L. Kaufman, A. Z. S. Rohatiner, Anjali S. Advani, James M. Foran, Georg Heß, Bertrand Coiffier, Myron S. Czuczman, Eva Giné, Simon Durrant, Michelle Kneissl, Kenneth T. Luu, Steven Y. Hua, Joseph Boni, Erik Vandendries, Nam H. Dang	119
14	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) 2013 ·Blood ·Peter Hillmen, Tadeusz Robak, Ann Janssens, (unknown), Sebastian Grosicki, Jiřı́ Mayer, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Thomas E. Boyd, Marco Montillo, Astrid McKeown, Jodi Carey, Ira Gupta, Chai‐Ni Chang, Steen Lisby, Fritz Offner	58
15	Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study 2011 ·Ghent University Academic Bibliography (Ghent University) ·Franck Morschhauser, J.F. Seymour, Pierre Feugier, Fritz Offner, Armando López‐Guillermo, (unknown), Lone Bredo Pedersen, Pauline Brice, David Belada, Luc Xerri, Gilles Salles	12
16	Pattern of infections observed during the maintenance phase in the PRIMA study 2011 ·Ghent University Academic Bibliography (Ghent University) ·Marie Bouteloup, John Seymour, Patrick Feugier, Fritz Offner, Armando López‐Guillermo, Réda Bouabdallah, (unknown), P. Brice, David Belada, Gilles Salles	1
17	Correlation of ZAP-70 analysed by flow cytometry with IgVH mutational status in B-CLL 2004 ·Ghent University Academic Bibliography (Ghent University) ·Jan Philippé, (unknown), (unknown), Femke Van Bockstaele, Ann Janssens, Fritz Offner	1
18	Bone marrow CD34⁺ cells generate fewer T cells in vitro with increasing age and following chemotherapy 1999 ·British Journal of Haematology ·Fritz Offner, Tessa Kerre, Magda De Smedt, Jean Plum	38
19	RELATIONSHIP OF SERUM CYTOKINES (TNF-ALPHA, IL-1-BETA, IFN-GAMMA AND INFLAMMATION MARKERS (NEOPTERIN, BETA-2-MICROGLOBULIN, C-REACTIVE PROTEIN) TO TRANSPLANT-RELATED COMPLICATIONS AND IMMUNOGLOBULIN PROPHYLAXIS FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION 1994 ·Ghent University Academic Bibliography (Ghent University) ·KM Sullivan, Fritz Offner, Manfred Herold, Masaru Mori, Christian G. Huber, D Niederwieser, FR Appelbaum, R Storb	1
20	MORTALITY HAZARD AS RELATED TO THE DURATION OF NEUTROPENIA AFTER MARROW TRANSPLANTATION 1994 ·Ghent University Academic Bibliography (Ghent University) ·Fritz Offner, Gary Schoch, Lloyd D. Fisher, Patrick Martin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact